Janney Montgomery Scott LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Janney Montgomery Scott LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,696 shares of the specialty pharmaceutical company's stock, valued at approximately $439,000.

Several other institutional investors and hedge funds have also made changes to their positions in COLL. Invesco Ltd. boosted its stake in Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical by 319.4% in the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after buying an additional 221,903 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $3,489,000. Raymond James Financial Inc. bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $2,432,000. Finally, F M Investments LLC bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $2,096,000.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director owned 70,658 shares of the company's stock, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded up $0.55 during trading hours on Monday, reaching $30.90. The stock had a trading volume of 431,680 shares, compared to its average volume of 399,434. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The firm has a 50-day simple moving average of $29.30 and a 200-day simple moving average of $29.51. The firm has a market capitalization of $992.82 million, a PE ratio of 25.33 and a beta of 0.64.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm's revenue was up 22.7% on a year-over-year basis. During the same period last year, the business earned $1.45 EPS. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical declared that its board has approved a stock buyback plan on Monday, July 7th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler restated a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.75.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.